RCEL20261016C2.5
RCEL Oct 16 2026 2.50 Call (RCEL261016C00002500)
option OPRA

avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company's lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.